Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.88 and traded as low as $0.63. Vaxart shares last traded at $0.66, with a volume of 1,919,722 shares trading hands.

Analyst Upgrades and Downgrades

Separately, B. Riley upgraded shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Wednesday, January 31st.

Vaxart Trading Down 7.2 %

The firm has a fifty day moving average of $1.13 and a two-hundred day moving average of $0.88. The company has a market cap of $116.43 million, a PE ratio of -1.14 and a beta of 0.44.

Vaxart (NASDAQ:VXRT) last announced its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03. Vaxart had a negative return on equity of 108.45% and a negative net margin of 1,117.56%. The company had revenue of $3.25 million during the quarter, compared to analyst estimates of $0.45 million. Sell-side analysts expect that Vaxart, Inc. will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxart

Institutional investors have recently made changes to their positions in the stock. AE Wealth Management LLC lifted its position in shares of Vaxart by 180.7% during the third quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 39,987 shares in the last quarter. Beacon Capital Management LLC lifted its position in shares of Vaxart by 369.9% during the fourth quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 40,000 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of Vaxart during the first quarter worth $32,000. Finally, PFG Investments LLC purchased a new position in Vaxart during the first quarter valued at approximately $38,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.